IMCR vs. LEGN, GRFS, TGTX, NUVL, LNTH, TLX, AXSM, CRSP, ADMA, and PCVX
Should you be buying Immunocore stock or one of its competitors? The main competitors of Immunocore include Legend Biotech (LEGN), Grifols (GRFS), TG Therapeutics (TGTX), Nuvalent (NUVL), Lantheus (LNTH), Telix Pharmaceuticals (TLX), Axsome Therapeutics (AXSM), CRISPR Therapeutics (CRSP), ADMA Biologics (ADMA), and Vaxcyte (PCVX). These companies are all part of the "pharmaceutical products" industry.
Immunocore vs. Its Competitors
Legend Biotech (NASDAQ:LEGN) and Immunocore (NASDAQ:IMCR) are both medical companies, but which is the better business? We will compare the two businesses based on the strength of their risk, analyst recommendations, earnings, media sentiment, dividends, profitability, institutional ownership and valuation.
70.9% of Legend Biotech shares are held by institutional investors. Comparatively, 84.5% of Immunocore shares are held by institutional investors. 0.0% of Legend Biotech shares are held by company insiders. Comparatively, 10.4% of Immunocore shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.
Legend Biotech currently has a consensus price target of $72.60, indicating a potential upside of 93.65%. Immunocore has a consensus price target of $58.89, indicating a potential upside of 76.95%. Given Legend Biotech's stronger consensus rating and higher probable upside, equities analysts plainly believe Legend Biotech is more favorable than Immunocore.
Legend Biotech has a beta of 0.19, meaning that its share price is 81% less volatile than the S&P 500. Comparatively, Immunocore has a beta of 0.77, meaning that its share price is 23% less volatile than the S&P 500.
Immunocore has a net margin of -6.48% compared to Legend Biotech's net margin of -29.95%. Immunocore's return on equity of -5.86% beat Legend Biotech's return on equity.
In the previous week, Legend Biotech had 11 more articles in the media than Immunocore. MarketBeat recorded 11 mentions for Legend Biotech and 0 mentions for Immunocore. Immunocore's average media sentiment score of 1.00 beat Legend Biotech's score of 0.41 indicating that Immunocore is being referred to more favorably in the news media.
Immunocore has lower revenue, but higher earnings than Legend Biotech. Immunocore is trading at a lower price-to-earnings ratio than Legend Biotech, indicating that it is currently the more affordable of the two stocks.
Summary
Immunocore beats Legend Biotech on 9 of the 16 factors compared between the two stocks.
Get Immunocore News Delivered to You Automatically
Sign up to receive the latest news and ratings for IMCR and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding IMCR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Immunocore Competitors List
Related Companies and Tools
This page (NASDAQ:IMCR) was last updated on 7/9/2025 by MarketBeat.com Staff
Free IMCR Stock Alerts